Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma – Exclusive China Partnership for Weekly GLP‑1 Diabetes Drug

Fineline Cube Mar 17, 2026
Company Deals

BeOne Innovation Center and Voyagers Capital Launch Fund – Early-Stage Drug Investment Vehicle Targets Guangzhou Biotech

Fineline Cube Mar 17, 2026
Company Deals

Ab&B Bio-Tech Partners with Walvax for Overseas Push – First China-Approved Trivalent Subunit Influenza Vaccine Targets Global Markets

Fineline Cube Mar 16, 2026
Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Fineline Cube Mar 13, 2026
Company Deals

APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio

Fineline Cube Mar 13, 2026
Policy / Regulatory

China Unveils NHSA Grassroots Healthcare Reform – 14‑Point Guidance Targets RMB Fund Flow Shift to Primary Care Institutions

Fineline Cube Mar 17, 2026
Company Drug

Henlius Wins NMPA Approval for HLX07 Combination Trial – Anti-EGFR Biologic Plus Serplulimab Targets Squamous NSCLC

Fineline Cube Mar 17, 2026
Company Drug

CSPC Pharma Secures Dual NMPA‑FDA Approval for PDE4B Inhaler SYH2059 – First‑in‑Class ILD Candidate Enters Global Clinical Development

Fineline Cube Mar 17, 2026
Company Drug

Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6‑Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer

Fineline Cube Jan 23, 2026

Daiichi Sankyo (TYO: 4568) announced that Raludotatug Deruxtecan (R‑DXd, DS‑6000a), a first‑in‑class CDH6‑targeted antibody‑drug conjugate (ADC),...

Company Deals

Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy

Fineline Cube Jan 23, 2026

Novo Nordisk (NYSE: NVO) and Canadian biotechnology firm Aspect Biosystems announced a new phase in their...

Company Deals

Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base

Fineline Cube Jan 23, 2026

Sisram Medical Ltd (HKG: 1696), an Israel‑based beauty and wellness group and part of Fosun...

Company Deals

BD and Ypsomed Develop Neopak XtraFlow 5.5mL Prefilled Syringe for YpsoMate Auto‑Injector

Fineline Cube Jan 23, 2026

Becton, Dickinson and Co. (BD) and Swiss injection system developer Ypsomed announced an expanded collaboration...

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026

Syngene International, a global contract research, development, and manufacturing organization (CRDMO), announced the extension of...

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that SHR‑7877 has received National Medical Products...

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026

PrimeGenX Therapeutics Co., Ltd., a Beijing‑based immune‑inflammatory disease specialist founded in 2016, has filed for...

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Fineline Cube Jan 23, 2026

Johnson & Johnson (J&J, NYSE: JNJ) reported fourth‑quarter revenue of $24.6 billion, up 9.1% year‑on‑year (YOY), bringing...

Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026

AbbVie Inc. (NYSE: ABBV) announced that China’s National Medical Products Administration (NMPA) has approved Risankizumab (SKYRIZI)...

Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026

Hangzhou Bio‑Sincerity Pharma‑Tech Co., Ltd. (SHE: 301096) announced a strategic cooperation agreement with Delim Cosmetics...

Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026

TaiGen Biotechnology and Joincare Pharmaceutical Group (SHA: 600380) announced a licensing agreement for the collaborative...

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026

China Isotope & Radiation Corporation (HKG: 1763) announced it has officially entered into a commercial...

Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026

Matwings Technology, a pioneer in AI‑driven protein engineering, announced a strategic biopharmaceutical pipeline collaboration with...

Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Fineline Cube Jan 22, 2026

Tianjin AmCellGene Co., Ltd. has granted Hong Kong‑based Advanced Regeneration exclusive regional rights to commercialize...

Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Fineline Cube Jan 22, 2026

Huadong Medicine Co., Ltd. (SHE: 000963), a leading China‑based pharmaceutical group, announced an exclusive commercialization...

Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026

AstraZeneca plc (AZ, NASDAQ: AZN) and Daiichi Sankyo Company, Limited (TYO: 4568) announced that Enhertu (trastuzumab deruxtecan)...

Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026

AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) has been officially approved in China for use...

Company Medical Device

HeartCare Medical’s Intracranial Drug‑Eluting Stent Gets NMPA Filing Nod

Fineline Cube Jan 22, 2026

Shanghai HeartCare Medical Technology Co., Ltd (HKG: 6609) announced that China’s National Medical Products Administration...

Company Medical Device

Abbott’s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe

Fineline Cube Jan 22, 2026

Abbott (NYSE: ABT) announced it has received CE Mark approval in Europe for the TactiFlex Duo...

Company Drug

Lilly’s Sofetabart Wins FDA Breakthrough Status for Platinum‑Resistant Ovarian Cancer

Fineline Cube Jan 22, 2026

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has...

Posts pagination

1 … 22 23 24 … 635

Recent updates

  • Shanghai Pharmaceuticals and Henlius Forge Strategic Alliance – Hospital Market Expansion and Global Commercial Collaboration Targeted
  • Henlius Wins NMPA Approval for HLX07 Combination Trial – Anti-EGFR Biologic Plus Serplulimab Targets Squamous NSCLC
  • CSPC Pharma Secures Dual NMPA‑FDA Approval for PDE4B Inhaler SYH2059 – First‑in‑Class ILD Candidate Enters Global Clinical Development
  • Basecare Medical Secures NMPA Approval for First Domestic‑Platform PGT‑A Kit – Milestone for China IVF Genetic Testing Independence
  • Alphamab Oncology Doses First Patient in JSKN027 Phase I Trial – First‑in‑Class PD‑L1/VEGFR2 Bispecific ADC Enters Clinic
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Shanghai Pharmaceuticals and Henlius Forge Strategic Alliance – Hospital Market Expansion and Global Commercial Collaboration Targeted

Company Drug

Henlius Wins NMPA Approval for HLX07 Combination Trial – Anti-EGFR Biologic Plus Serplulimab Targets Squamous NSCLC

Company Drug

CSPC Pharma Secures Dual NMPA‑FDA Approval for PDE4B Inhaler SYH2059 – First‑in‑Class ILD Candidate Enters Global Clinical Development

Medical Device

Basecare Medical Secures NMPA Approval for First Domestic‑Platform PGT‑A Kit – Milestone for China IVF Genetic Testing Independence

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.